SURMOUNT-1 (tirzepatide, 72 weeks): Discontinuation due to AEs: 4.3% (5 mg), 7.1% (10 mg), 6.2% (15 mg) vs 2.6% placebo Key characteristics: GI events occur primarily during dose escalation The GIP component does not appear to add substantial GI burden beyond GLP-1 effects Pooled SURMOUNT-1 to -4 analysis showed treatment discontinuation due to GI AEs ranged from 1.0% to 10.5% Retatrutide# Retatrutide adds glucagon receptor agonism to GLP-1 and GIP, creating a triple agonist
The benefits of acetyl-L-carnitine It may support youthful memory function, improve mitochondrial structure and function, inhibit age-related oxidative damage and restore the activity of key enzymes
Q: How is this different from a standard body wash
Whether you're just starting out or looking for ongoing support, Levity's programs are built to adapt to your goals and your life
During your consultation in Nashville, our team will outline a realistic timeline for your personalized GLP Activate journey
SA--Galactosidase marker research in senescent cells